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South African (SA) researchers have made both national and global contributions to HIV prevention and treatment. Research conducted 
in SA has contributed markedly to improved survival in HIV-infected infants, children and adults. The translation of clinical research into 
practice has enabled the curtailment of paediatric HIV in SA. Along with international collaborators, SA has made pivotal contributions 
to biomedical prevention modalities including medical male circumcision and oral and topical microbicides, and is undertaking pivotal 
HIV vaccine research. Research into the structural and psychosocial drivers of HIV infection will be critical for sustaining biomedical 
interventions, and necessary to end AIDS. 
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The graph of our region’s life expectancy shows a peculiar dip in the 
1990s that persists for a decade.[1] Those who were on the forefront – 
communities and their healthcare workers – can discern the cause 
of that dip through personal experience. HIV/AIDS went on to 
devastate South Africa (SA), overwhelming a fragile healthcare system 
not yet repaired from the damage of apartheid, killing the young 
and economically active in vast numbers, spreading stigma, leaving a 
generation of orphans and blotting the legacy of the political regime that 
rubber-stamped the avoidable deaths of over 300 000 South Africans 
by propagating AIDS denialism. By the mid-2000s, the graph begins 
to recover,[1] a testament to the human effort of the health activists, 
researchers and healthcare workers who contributed to alleviating the 
health crisis of our time. SA’s force of HIV researchers can point to that 
recovery in the graph and say, ‘We had a part to play in this.’ 
SA, with the largest HIV epidemic in the world, estimated at 7.52 
million people living with HIV, still sees too many AIDS-related deaths: 
115  167 people died of AIDS in 2018.[2] Although the death toll has 
substantially reduced, from 283 564 in 2006,[3] it is still too high for 
an era in which sophisticated treatments are available (Fig. 1).[4] New 
infections continue: the estimate of 231 000 new infections in 2017[5] is 
a rallying call toward strengthening preventive efforts.
Here we summarise the past, current and anticipated future 
contributions of HIV research in SA to help quell our epidemic.
How HIV affects life and death in SA
In 2005, the year after the public anti retroviral treatment (ART) 
programme had its limited launch, average life expectancy in SA 
reached a low point of 51.9 years for men and 55.5 for women.[4] By 
2017, life expectancy was 61.2 and 67.4 years for men and women, 
respectively.[4] This dramatic progress is attributed to the decline in HIV-
related mortality, specifically in young adults accessing treatment,[6] and 
in infants who avoided HIV infection thanks to ART-based prevention 
of mother-to-child transmission (PMTCT) strategies.[4] 
Among adolescents and young adults, particularly women, HIV/
AIDS has had a deadly effect in SA. The probability of a 15-year-old SA 
girl dying before the age of 25 was influenced by the country’s response 
to HIV: this statistic peaked at the height of the untreated epidemic 
in 2004, and then significantly reduced in the era of ART availability 
Fig. 1. Trend in the number of natural and unnatural deaths by broad age group, 2000 - 2017. (HIV-related deaths are classified as natural deaths.)[4]
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(Table 1).[4] In parallel, infant and under-5 mortality rates are also 
declining in SA, and in 2017 were 23 and 32 per 1 000 live births, 
respectively – on track to meet the 2019 targets.[4] 
Changing the trajectory of the HIV 
epidemic through research and 
implementation of ART
In 2004, SA launched what has since grown into the largest ART 
programme on the planet.[5] During this time, there have been 
significant advances in treatment science, which have been adopted 
in programmatic implementation. Key examples of the country’s 
research-to-implementation model informing the success of the ART 
programme include (i) ART initiation eligibility for children and 
adults;[7,8] and (ii) task-shifting from an elite subset of ‘HIV doctors’ 
to HIV-trained nurses.[9,10] 
Discovery of improved strategies for determining 
eligibility for ART initiation, and their implementation 
Conducted in SA during a time when children had to meet steep 
immunological, virological and clinical criteria to start ART,[11] the 
Children with HIV Early Antiretroviral Therapy (CHER) study had 
startling findings: early HIV diagnosis and ART initiation reduced 
early infant mortality by 76%, and HIV progression by 75%.[7] The 
study influenced local and international clinical guidelines to treat 
children at diagnosis, translating into improved paediatric HIV 
outcomes globally.[11,12]
SA researchers also contributed to a study that influenced the 
change in adult treatment eligibility guidelines. The Strategic 
Timing of Antiretroviral Treatment (START) study, conducted in 
35 countries including SA, showed that immediate ART initiation at 
CD4+ counts >500 cells/µL was superior to deferring ART initiation 
until the CD4+ count was <350 cells/µL.[8] 
SA researchers, faced with a significant HIV/TB comorbidity 
problem, provided evidence for the timing of ART initiation after TB 
treatment. ART initiation within 4 weeks of TB treatment increased 
AIDS-free survival for patients with CD4+ counts <50 cells/µL. 
However, ART initiation ought to be deferred to the first 4 weeks of 
the continuation phase of TB treatment in those with higher CD4+ 
T-helper cell counts.[13,14] 
The newest SA guidelines recommend a first-line dolutegravir-
based regimen to replace the efavirenz component, minimising the 
side-effect profile and prolonging durable virological suppression.[15] 
Studies researching further ART regimen optimisation include 
WRHI 052,[16] which suggests that switching from a ritonavir-boosted 
lopinavir nucleoside-analogue-based regimen to a daily low-dose 
ritonavir-boosted darunavir nucleoside-analogue-based regimen 
after viral suppression might be safe and efficacious. The ADVANCE 
study is investigating a candidate universal ART regimen, including 
the replacement of tenofovir disoproxyl fumarate with tenofovir 
alafenamide.[17] 
The evidence of good outcomes with task-shifting opens 
the way for ART scale-up 
Researchers in SA conducted two landmark studies on task-
shifting, one through the Comprehensive International Program 
for Research in AIDS in SA (CIPRA SA), and the other called 
the Streamlining Tasks and Roles to Expand Treatment and 
Care for HIV (STRETCH) study. Both proved that task-shifting 
was not deleterious to patient outcomes, thereby facilitating the 
scale-up of the SA ART programme to reach the millions of 
people living with HIV needing treatment initiation and lifelong 
monitoring.[9,10] 
PMTCT: The SA commitment to 
protecting babies and mothers
SA has been at the forefront of PMTCT research. As evidence mounted 
from research in high-income settings about the effectiveness of ART for 
PMTCT, scientists in SA sought to determine whether such regimens 
were feasible for wide-scale implementation in low- and middle-income 
health-system contexts with breastfeeding populations. The multi-
country PErinatal TRAnsmission (PETRA) trial (1996 - 2000),[18] which 
included two SA sites, assessed the efficacy of three different short-course 
antiretroviral (ARV) regimens. The PETRA trial showed that short-
course ARV regimens effectively reduced intrapartum transmission, but 
that additional measures were needed to prevent postnatal breastmilk 
transmission.[18] After maternal-infant administration of single-
dose nevirapine (sdNVP) was found to be moderately efficacious 
and affordable, SA scientists designed the South African Intrapartum 
Nevirapine Trial (SAINT) to evaluate whether an additional maternal 
dose of NVP could further reduce transmission rates. The trial 
demonstrated the efficacy of two inexpensive regimens given during 
labour in reducing intrapartum and early postpartum transmission.[19] 
However, the two maternal doses of NVP were found to increase the 
prevalence of NVP resistance. Given the high rates of non-nucleoside 
reverse-transcriptase inhibitor (NNRTI)-resistance mutations in most 
women and HIV-infected infants receiving NVP, including sdNVP, 
a study to assess adding a short course of zidovudine (AZT) and 
lamivudine (3TC) was designed and conducted in SA. This intervention 
was found to reduce emergent resistant mutations in both mothers and 
their infants, and was incorporated into clinical care.[20] 
After the demonstration of short-course antiretroviral therapy for 
PMTCT, the WHO published technical notes on PMTCT stating that 
‘there was no longer any justification to restrict use of any of these 
regimens to pilot project or research settings’.[21] Following a Constitutional 
Court battle against the National Department of Health (NDoH) by the 
Treatment Action Campaign, the SA government began, in 2003, to scale 
up an NVP-based PMTCT programme from two pilot sites per province 
to reach national coverage.[22] Although early MTCT rates declined after 
the scale-up of single and short-course regimens in SA, the challenge 
remained as to how to prevent postnatal transmission through breastmilk, 
and how to improve maternal health.[23,24] Researchers in Soweto evaluated 
the role of post-exposure prophylaxis in preventing post-partum 
transmission, which led to the multi-centre HPTN 040 trial. This trial 
assessed three post-partum interventions to prevent HIV transmission[25] 
and changed clinical guidelines for post-partum prophylaxis for HIV-
exposed infants whose mothers had been undiagnosed during pregnancy 
and labour.[26]
Research undertaken in SA, one of only a few African countries 
that provided free formula milk to HIV-infected mothers, provided 
evidence regarding HIV outcomes related to infant feeding choices.[27,28] 
A study conducted in KwaZulu-Natal Province found that exclusive 
breastfeeding carried a significantly lower risk of HIV-1 transmission 
than mixed feeding, and a similar risk to exclusive formula feeding.[29] 
These findings were confirmed in another study at the rurally-located 
Africa Centre, which also documented higher mortality among 
infants given replacement feeds compared with those exclusively 
Table 1. Probability per 1 000 of a 15-year-old SA female 
dying before age 25 years[4]
Year Probability 
2000 35.1
2004 44.4
2017 17.0
SA = South African.
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breastfed.[30] These two studies guided the 
2009 WHO recommendations on HIV and 
infant feeding towards exclusive breastfeeding 
for 6 months, and continued breastfeeding 
until 12 months old, together with ART.[2,31]
PROMISE (2011 - 2015), a landmark 
multi-country trial that included sites in 
SA, investigated the benefits and risks of 
combination ART given to pregnant women 
with a CD4+ count of at least 350 cells/µL 
compared with short-course AZT and 
sdNVP. PROMISE proved that antenatal 
ART resulted in significantly lower rates of 
early HIV transmission than zidovudine 
alone,[32] which led to the decision by the SA 
government in 2015 to recommend starting 
lifelong ART for pregnant HIV-positive 
women, irrespective of CD4+ count. These 
evidence-informed policy changes led to 
dramatic improvements in the health and 
survival of women and children, such that by 
2015, HIV was no longer the leading cause of 
under-5 deaths, and had declined significantly 
as a contributor to maternal deaths.[33] These 
successes have created an important area for 
current research, namely the health of HIV-
exposed uninfected children, the focus of 
another article in this supplement.[34]
SA scientists have also contributed 
important health-systems research, 
undertaken across the continent, regarding 
strategies to improve the implementation 
of PMTCT policies in primary healthcare 
settings,[35-37] and the role of community 
cadres in strengthening linkages between 
households and health facilities.[38,39] 
Future research in SA will be aimed at 
reducing the residual risk of breastmilk 
transmission, possibly including novel 
interventions such as passive immunisation 
with broadly neutralising antibodies or active 
vaccination strategies.
HIV prevention research 
and interventions in SA
From 2011 to 2016, there has been a 34% 
decrease in new HIV infections among 
15 - 49-year-olds in SA.[40] Contributors to the 
decline include: (i) increased ART uptake;[41] 
(ii) the scale-up of voluntary medical male 
circumcision to 2.4 million procedures 
conducted between 2012 and 2016 alone;[40] 
(iii) increased condom distribution;[40,41] 
and (iv) increased availability of HIV testing 
services at over 4 500 public healthcare facilities, 
which tested 13 million South Africans within 
18  months.[42,43] SA has contributed much 
research evidence on HIV prevention, 
including the protective effects of medical 
male circumcision on male HIV acquisition,[44] 
treatment of people living with HIV as 
prevention to HIV-uninfected partners[45] and 
the proven lack of efficacy of the diaphragm in 
preventing HIV acquisition.[46] 
In 2016, SA began the rollout of pre-
exposure prophylaxis (PrEP) to sex 
workers.[47] PrEP services were extended 
to men who have sex with men (MSM) 
and to adolescent girls and young women 
between 2018 and 2019,[40] with plans for 
provision to postpartum women, and for 
high-transmission areas. The effectiveness 
of oral and topical PrEP, which is closely 
tied to adherence, has varied across studies 
conducted in different populations. Generally, 
oral PrEP effectiveness has been high among 
MSM in high-income countries.[48,49] Studies 
conducted among women in SA have yielded 
different results. The effectiveness of oral 
Truvada as PrEP has ranged between –4% 
(VOICE)[50] and 6% (FEMPREP)[51] in 
African trials, and poor adherence has been 
implicated.[50,51] The effectiveness of topical 
tenofovir gel microbicide, an SA initiative, 
ranged between 0% (FACTS 001),[52] 15% 
(VOICE)[50] and 39% (CAPRISA 004).[53] 
Again, poor adherence was implicated. Such 
findings, shown in Table 2, highlight the 
ongoing need for a regionally acceptable 
method of HIV prevention, especially for 
young women in Africa, who are a most-
at-risk population for HIV acquisition. The 
ASPIRE and RING trials found that the 
intravaginal dapivirine ring had modest 
efficacies of 27% and 31%, respectively.[54,55]
Table 2. Summary of ARV-based PrEP trials in SA showing low to modest efficacy
Prevention trial Trial 
name
Trial 
site
Participants Effectiveness, 
%
Topical tenofovir gel, coital CAPRISA 004 SA Women 39
FACTS 001 SA Women 0
Topical tenofovir gel, daily MTN003/VOICE SA, Uganda, Zimbabwe Women 15
Oral Truvada, daily iPrex Americas, Thailand, SA MSM/transgender 44
FeMPrEP Kenya, SA, Tanzania Women 6
MTN003/VOICE SA, Uganda, Zimbabwe Women –4
Oral tenofovir, daily MTN003/VOICE SA, Uganda, Zimbabwe Women –49
Dapivirine ring RING SA, Uganda Women 31 (0 in 18 - 21 yrs)
ASPIRE/MTN020 Malawi, SA, Uganda, Zimbabwe Women 27 (0 in 18 - 21 yrs)
ARV = antiretroviral; PrEP = pre-exposure prophylaxis; SA = South Africa; MSM = men who have sex with men.
Fig. 2. Study tracks of the Pox-Protein Public-Private Partnership (P5), which is investigating 
vaccines against HIV clade C (the South African Medical Research Council is one of the P5 
partners). (SA = South Africa.) *Participants.
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SA contributions to the search for a 
preventive HIV-1 vaccine 
SA has adopted multiple HIV prevention tools into the public health 
system, including barrier methods, male medical circumcision and 
ARV prophylaxis strategies.[56] However, new infections continue 
to amass.[5] The challenges of current HIV prevention methods 
include resource constraints, reliance on daily adherence, patriarchal 
power imbalances and method unsuitability for women  – the sex 
that experiences disproportionate infection risk.[57] As with other 
pathogens, a vaccine could cost-effectively deliver us to a tipping point 
in HIV control.[58,59] 
For over 18 years, SA has contributed to the pursuit of a 
preventive HIV vaccine.[57] In collaboration with community, local 
and international stakeholders, the SA Medical Research Council 
(SAMRC), through the SA AIDS Vaccine Initiative (SAAVI), has 
pioneered studies of vaccines against the clade C HIV subtype 
responsible for the highest number of global HIV infections, such as 
the SAAVI-developed DNA.C and recombinant MVA vaccines.[60,61] 
The SAMRC-led SAAVI programme was a public-private partnership 
funded by the NDoH, Department of Science and Technology and 
Eskom, which, after a 9-year development period, created a pipeline 
of candidate HIV-1 subtype C vaccines. These included virus-like 
particles, novel DNA plasmid vaccines, capripoxvirus and Bacillus 
Calmette-Guérin (BCG)-vectored vaccines.[62] 
The research of an HIV vaccine has required much persistence. 
In the evaluation of the MRK-Ad5 HIV vaccine, the SA HVTN 503/
Phambili trial was stopped early after the declaration of futility of its 
companion study in the Americas, the HVTN 502/Step trial. A finding 
that halted further Adenovirus 5 platform development was that MRK-
Ad5 increased the susceptibility to HIV in male volunteers, irrespective 
of circumcision and Ad5 serostatus.[63,64]
Since the 2009 milestone announcement in Thailand of the first 
vaccine regimen with some efficacy,[65] the SAMRC, as part of the 
Pox-Protein Public-Private Partnership, has collaborated in the 
development of a similar heterologous prime-boost regimen for 
clade C (Fig. 2). When South Africans were vaccinated with the Thai 
regimen, the initially robust cross-clade immune responses were 
not durable.[66] However, the addition of a booster to the clade-C 
adapted regimen prolonged immune responses.[67] The latter regimen 
has progressed to an efficacy trial, HVTN 702/Uhambo,[67] which is 
chaired by four female SA medical researchers. HVTN 702/Uhambo 
completed enrollment in July 2019 at its 14 SA sites. In parallel, results 
of other vaccine trials show that replacing the pox vector with a DNA 
plasmid vaccine prime can also induce relevant immune responses. 
The potential for easy and cheap manufacturing of DNA plasmid 
vaccines makes this avenue promising.[68]
SA researchers are also contributing to the clinical development of a 
global antigen HIV vaccine. An early-phase trial of a prime-boost vaccine 
strategy evaluating a mosaic adenovirus-26 vector and clade  C  gp140 
protein conducted across three continents (Africa, Asia and North 
America) produced robust immune responses, comparable with those 
found to be efficacious in preclinical studies.[69] These findings led to the 
implementation of the HVTN 705/VAC89220HPX2008/Imbokodo 
phase 2b efficacy trial currently underway in sub-Saharan Africa 
(SSA), including 17 SA sites.[70] 
Passive immunisation with monoclonal antibodies (mAb) is 
another promising strategy that has been shown to be protective in 
preclinical studies.[71,72] The first phase 2b human trial investigating 
preventive efficacy of the VRC01 mAb is underway in SSA. SA 
scientists have also identified a neutralising antibody, CAP256, 
which is highly potent against clade C HIV, and about to enter early 
clinical development.[73,74] 
Future focus of research
We still need to find solutions to the underlying structural, 
psychosocial and behavioural drivers of the HIV epidemic. Key to 
epidemic control will be the engagement of young people and key 
populations such as sex workers, their clients and MSM, to ensure 
the uptake of biomedical interventions as well as address issues of 
intimate partner violence, intergenerational sex and patriarchy.[75-85] 
SA research has exposed gender-based violence as a key driver of HIV 
acquisition.[81] Gender-based violence is endemic across SA, driving 
mental health concerns,[75,84-86] both of which are associated with poor 
health-seeking behaviours and poor adherence to medications.[87-90] 
Attention to designing interventions that ensure access to HIV 
prevention, treatment and care for adolescent girls and young adults 
may contribute to breaking the transmission cycle. Future research 
should also focus on understanding the HIV epidemic in men, and 
factors associated with transmission, such as intergenerational and 
transactional sexual partnerships.
Conclusion
The small community of SA researchers, supported by their 
communities, study participants, collaborations and sponsors, has 
made key scientific contributions that inform public programmes on 
changing the course of the HIV epidemic, and improving public health.
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